Resumen de Anti-tnf dose and anti-drug antibody levels in rheumatic and psoriasis patients: Economic repercussion
M. A. González Fernández, Francisco Moreno Ramos, Adolfo Varela Hugo, Chamaida Plasencia, Dora Pascual Salcedo, Pedro Herranz Pinto, Alicia Herrero Ambrosio
Introduction: In our hospital, the detection of anti-TNF and anti-drug antibody levels are used in clinical practice and can aim the clinicians to provide a safe and an efficient therapy.
Objective: To analyse the economic impact of the biological therapy optimization in patients with rheumatic and psoriasis by monitoring the drug and anti-drug antibody serum levels.
Method: Ambispective observational study. The retrospective study period extended from 2009 to 2012 and includes the results without optimization. The prospective study period started in 201 and includes financial results with doses and administration intervals optimized. Drugs most frequently implicated were infliximab, etanercept and adalimumab.
Results: We checked doses and administration intervals of 449 adults with rheumatic diseases (41.8% under optimized regimen) and 167 patients with psoriasis (38.9% under optimized regimen) in 2013. The annual cost per average patient decreased by €1,345 in arthritic diseases and by €1,417 in psoriasis compared to the previous year.
Conclusion: Optimized treatments are more efficient, leading to a reduction in the annual costs per average patient. The access to the clinical information of patients and the integration of pharmacists into multidisciplinary teams alongside provide a better high-quality pharmaceutical care, and evaluation of economic and clinical results
